Small Renal Mass Surveillance: Histology-specific Growth Rates in a Biopsy-characterized Cohort

The Current Evidence for Factors that Influence Treatment Decision Making in Localized Kidney Cancer: A Mixed Methods Systematic Review

“…Across cancer care, biopsies have long been used to contextualise a cancer diagnosis in respect to type, grade and potential treatment options 60 . A recent study by Finelli et al confirmed the importance of biopsies in respect to progression rates amongst kidney cancer subgroups 61 , which ultimately may enable clinicians to present patients with options to avoid overtreatment and treatment complications. 61,62 .…”

Delaying surgery for clinical T1b-T2bN0M0 renal cell carcinoma: Oncologic implications in the COVID-19 era and beyond

“…Active surveillance (AS) literature has demonstrated that urologists can safely monitor most cT1a renal masses [ 4 , 7 , 8 ]. However, for cT1b-cT2b masses this is less clear.…”

Novel Liquid Biomarkers and Innovative Imaging for Kidney Cancer Diagnosis: What Can Be Implemented in Our Practice Today? A Systematic Review of the Literature

“…The rationale for the second assumption was to ensure generalisability to routine clinical practice. Of note, the rationale for the third assumption was that although misclassification of RCCs as "benign" renal masses may not necessarily lead to detrimental prognostic implications (ie, histologically malignant, biologically "indolent" renal masses may be initially followed with active surveillance without compromising the ultimate oncological outcome [100]), in light of the current uncertainties in predicting SRM clinical heterogeneity and considering the latest guideline recommendations [9,10], in a real-life scenario the discrimination between malignant and benign renal masses before decision-making on definitive treatment remains the most compelling priority for clinicians. Thus, to be of value in clinical practice, any novel test for RCC diagnosis should still favour sensitivity over specificity.…”